Tumor-associated mutant forms of p53 can exert an antiapoptotic gain of function activity, which confers a selective advantage upon tumor cells harboring such mutations. We report that mutant p53 suppresses the expression of the MSP (MST-1/HGFL) gene, encoding the ligand of the receptor tyrosine kinase RON, implicated in a variety of cellular responses. Mutant p53 associates with the MSP gene promoter and represses its transcriptional activity, leading to a decrease in mRNA levels and a subsequent decrease in the levels of secreted MSP protein. Forced downregulation of MSP expression in H1299 cells, derived from a large-cell lung carcinoma, confers increased resistance against etoposide-induced cell death. These antiapoptotic consequences of MSP downregulation seemingly conflict with the well-documented ability of the RON receptor to promote cell survival and tumor progression when aberrantly hyperactive. Yet, they are consistent with the fact that reduced MSP expression was observed in many types of human cancer, including large-cell lung carcinoma. Thus, repression of MSP gene expression by mutant p53 may contribute to oncogenesis in a cell type-specific manner.
Introduction
The p53 tumor-suppressor gene serves as an effective barrier against cancer. As a result, tumor cells in which p53 is inactivated are often selected during the course of tumor progression. Close to half of all human tumors harbor mutations within the p53 locus. In much of the remainder, the impact of p53 is functionally attenuated due to aberrations in the levels or function of proteins that act either upstream or downstream of p53 (reviewed in Vogelstein et al., 2000; Bargonetti and Manfredi, 2002; Vousden and Lu, 2002; Oren, 2003) . p53 suppresses tumor formation through a number of parallel mechanisms. The majority of these cellular mechanisms rely on p53's ability to act as a potent sequence-specific transcriptional activator, resulting in the transcriptional upregulation of a variety of p53 target genes. When trans-activating its targets, p53 binds to specific sequences in the DNA, denoted p53 response elements (p53REs) and recruits the transcriptional machinery of the cell. The importance of p53's DNAbinding ability is underscored by the fact that the vast majority of p53 mutations occur within its DNAbinding domain (el-Deiry, 1998; Soussi, 2000) . In addition, wild-type p53 (wt p53) activation results in the transcriptional repression of many other genes, most of which do not possess p53REs (Hoffman et al., 2002) .
In view of its central role in tumor prevention, it is no surprise that the p53 gene is subjected to frequent mutational inactivation in human cancer. However, unlike most other tumor-suppressor genes, such as Rb and Arf, which are typically deleted, truncated or silenced (Harbour and Dean, 2000; Serrano, 2000) , p53 gene mutations usually result in accumulation of high levels of full-length mutant protein (Sigal and Rotter, 2000; Cadwell and Zambetti, 2001; Kim and Deppert, 2004) . Moreover, analysis of the mutation spectrum of p53 in tumors has identified several mutational 'hotspots', including the R175H, R248W and R273H mutants. Abundant evidence suggests that these 'hotspot' mutants possess novel oncogenic gain of function activities, which are manifested both in tissue culture and in in vivo experimental models (Sigal and Rotter, 2000; Cadwell and Zambetti, 2001; Kim and Deppert, 2004) . Thus, tumor-associated forms of mutant p53 can contribute to the disruption of the spindle checkpoint control (Gualberto et al., 1998) and promote genomic instability (Murphy et al., 2000) , as well as accelerate tumorigenesis in mice (Dippold, 1993; Wolf et al., 1984) . Of particular note, such mutants can exert antiapoptotic effects under a variety of stress inducing conditions, and increase the resistance of cultured cells to killing by clinically relevant anticancer agents (Lotem and Sachs, 1995; Li et al., 1998; Blandino et al., 1999; Matas et al., 2001) .
The common types of p53 mutations found frequently in human cancer target the DNA-binding domain of the protein, and abolish its ability to bind p53REs and activate the majority of the typical wt p53 target genes. Nevertheless, tumor-associated forms of p53 do possess an ability to modify gene expression patterns (Kim and Deppert, 2004) ; in fact, mutant p53 is able to augment the expression of specific target genes while repressing that of others. For instance, tumor-associated p53 mutants have been reported to activate the genes encoding c-Myc (Frazier et al., 1998) , topoisomerase I (Albor et al., 1998) , the multidrug resistance MDR-1 protein (Chin et al., 1992; Zastawny et al., 1993; Sampath et al., 2001) , the antiapoptotic protein BAG-1 (Yang et al., 1999) , and the EGR1 transcription factor (Weisz et al., 2004) , as well as a variety of additional genes (Scian et al., 2004a, b) . Different p53 mutants also retain the ability to activate different subsets of genes from the repertoire of wt p53 target genes, and this imbalanced selective activation may also contribute to varying degrees to their gain of function effects (Blagosklonny, 2000; O'Farrell et al., 2004) . Mutant p53-repressed genes have so far been studied in less detail, but at least one relevant example is the CD95/Fas gene, encoding a death receptor. As reported by us previously, various p53 mutants are capable of binding and repressing the CD95 promoter, thereby conferring increased resistance to killing by the CD95/Fas ligand, and probably also contributing to some extent to the ability of cancer cells to withstand DNA damageinduced apoptosis (Zalcenstein et al., 2003) .
Here, we report that mutant p53 can also downregulate the gene encoding Macrophage Stimulating Protein (MSP), also known as HGFL (Hepatocyte Growth Factor Like) or MST-1 (Macrophage STimulating factor-1). MSP belongs to the plasminogenrelated kringle protein family and is a heterodimeric protein produced by cleavage of its 78 kDa precursor (reviewed in Danilkovitch-Miagkova and Leonard, 2001; Camp et al., 2005) . MSP shares 45% homology with hepatocyte growth factor (HGF), and similar to HGF, it has been implicated in the activation of growth and motility pathways (Iwama et al., 1996; Sakamoto et al., 1997) through its interaction with its target receptor RON.
The MSP/RON signaling pathway is responsible for a wide variety of cellular activities (reviewed in Danilkovitch-Miagkova and Leonard, 2001; Camp et al., 2005) . Mice devoid of MSP reach adulthood normally without any discernable phenotype except for development of lipid-containing cytoplasmic vacuoles in their hepatocytes (Bezerra et al., 1998) . The consequences of RON genetic inactivation are more complex and somewhat debatable. One study reported that RON knockout results in embryonic lethality due to inability to undergo uterine implantation (Muraoka et al., 1999) . However, another group was able to obtain viable RONÀ/À mice, and showed that such mice exhibited significantly higher levels of NO production and altered IFN-g-mediated immune responses (Correll et al., 1997) . Excessive activation of the MSP/RON pathway has been shown to play a positive role in carcinogenesis, particularly at advanced stages of tumor progression (reviewed in Wang et al., 2003) . The oncogenic effects of excessive RON activity are probably due, at least in part, to decreased cell adhesion and increased cell migration (Willett et al., 1998) , which may contribute to neoplastic transformation in vitro and tumor metastasis in vivo (Peace et al., 2001) .
Numerous studies have implicated aberrant activation of the MSP/RON pathway in increased survival of cancer cells (reviewed in Danilkovitch-Miagkova and Leonard, 2001; Wang et al., 2003 Wang et al., , 2005 . Hence, MSP is generally considered to exert antiapoptotic effects. Nevertheless, this is not always the case: Iwama et al. (1996) reported that, depending on cell type, MSP can either promote apoptosis or prevent it, in the latter case inducing cell proliferation.
Whereas aberrant excessive RON activation often acts to reduce apoptosis and promote cancer, less is known about the significance of normal RON function in this context. In fact, it appears that when properly regulated, the MSP/RON pathway does not contribute to cancer (Camp et al., 2005) . Indeed, as reported here, several types of tumors exhibit a significant reduction in MSP gene expression, compared to the corresponding normal tissues. We show that downregulation of MSP expression can render human lung cancer-derived cells more resistant to DNA damage-induced apoptosis, suggesting that under such circumstances the endogenous MSP protein is actually contributing to apoptosis, rather than preventing it. Thus, repression of MSP expression by mutant p53, when occurring in particular types of tumor cells, may increase illegitimate survival and thereby promote cancer progression.
Results

The MSP gene is downregulated by mutant p53
In an effort to identify genes specifically regulated by mutant p53, the gene expression profiles of p53-null, human large-cell lung carcinoma-derived H1299 cells and their derivatives stably overexpressing mutant p53 were compared using Affymetrix DNA microarrays. In order to increase the statistical validity of the study and reduce clonal variability, RNA samples derived from several different stably transfected clones were pooled together in equal portions before cDNA synthesis. Genes whose expression levels were affected by mutant p53, that is, either upregulated or downregulated, were identified (Weisz et al., 2004) . This group might comprise both genes that are directly regulated by mutant p53 (e.g. by binding of the mutant p53 protein to their promoter) and genes whose expression is indirectly affected by mutant p53 overexpression. One gene whose expression was consistently found in the microarray analysis to be attenuated in the presence of mutant p53 was MSP (data not shown). Downregulation of MSP mRNA in H1299 cells stably expressing mutant p53 could be confirmed by real-time RT-PCR analysis ( Figure 1a To determine whether the reduction of MSP expression by mutant p53 was due to repression of the MSP gene promoter, we monitored the effect of cotransfected mutant p53 on a plasmid in which the expression of a luciferase reporter gene was driven by regulatory DNA elements derived from the human MSP gene (MSP-luc). As seen in Figure 1c , cotransfection of mutant p53 (R175H) significantly reduced MSP-luciferase activity in H1299 cells. Thus, the MSP promoter is a target for transcriptional repression by mutant p53. Of note, the levels of transfected mutant p53 at which the repressive effect on MSP was observed were comparable to those present in cancer-derived cell lines such as SKBR3 and SW480 (Figure 1d ).
Mutant p53 is physically associated with the MSP promoter The mechanism by which mutant p53 affects the expression of various genes is not yet fully resolved. To investigate the possibility that, similarly to what has been found for other genes such as CD95 (Zalcenstein et al., 2003) and EGR1 (Weisz et al., 2004) , mutant p53 interacts physically with the MSP promoter, we performed chromatin immunoprecipitation (ChIP). H1299 cells expressing either wt p53, mutant p53 (R175H) or no p53 were crosslinked, harvested and subjected to ChIP with an anti-p53 polyclonal antibody, followed by RT-PCR analysis with primers corresponding to the MSP promoter. As is evident from Figure 2 (mp53 lane), mutant p53 was found to associate specifically with the MSP promoter. Interestingly, a positive albeit weaker signal was also obtained with wt p53, indicating that the latter can also interact with the MSP promoter.
Downregulation of MSP results in attenuation of apoptosis following DNA damage
We next wished to test the biological effects of MSP downregulation. To this end, we generated short hairpin RNA (shRNA) expression plasmids specific for MSP, based on the pSuper vector (Brummelkamp et al., 2002) . Several such plasmids were tested for their ability to (R175H) or an empty vector (pCMV-neo-Bam) were seeded in six-well plates. After 24 h, cells were harvested and total RNA was extracted. Equal amounts of RNA from several clones were pooled together, and 2 mg of each RNA pool was used as a template for reverse transcription. Real-time PCR was performed with primers specific for either MSP or GAPDH mRNA. Relative MSP mRNA levels were calculated by normalization of the MSP value for the amount of GAPDH transcripts in the same sample; results are shown in arbitrary units. (b) H1299 cells were transfected with either p53R175H or p53R273H expression plasmids or empty vector (control). Following 2 weeks of drug selection, single-cell clones were isolated. Equal amounts of total RNA, obtained from individual clones expressing either p53R175H or p53R273H, were pooled together (separately for each p53 mutant) before cDNA synthesis. cDNA was subsequently prepared and RNA levels of MSP and GAPDH were determined by semiquantitative RT-PCR. (c) H1299 cells were seeded in 24-well culture dishes. Each well was transfected with 0.2 mg of MSP-luciferase reporter plasmid DNA together with 100 ng of either pCMV-neo-Bam vector control (cont) or mutant p53R175H expression plasmid. Each plasmid combination was transfected into six identical wells. Luciferase activity was assayed 48 h post-transfection, and is shown in arbitrary machine units. The average and standard error are shown. (d) A total of, 100 000 H1299, SKBR3 and SW480 cells were seeded in six-well plates. H1299 cells were transfected with either 0.5 mg of a control plasmid or a plasmid expressing mutant p53 (R175H). The cells were collected 48 h later, and subjected to SDS-PAGE followed by Western blot analysis with p53-specific antibodies (see Materials and methods).
downregulate the levels of secreted MSP in the cell culture medium; it is noteworthy that the main form of MSP detected in the culture medium was the processed, active form, most probably generated through processing of the 78 kDa primary translation product by serum kallikrein and additional serum proteases (Wang et al., 1994) . Two MSP shRNA expression plasmids were found to be effective to varying degrees ( Figure 3a ): plasmid #1 was of moderate efficacy, whereas #2 was of higher efficacy (compare residual MSP protein levels to the GAPDH loading control). It is noteworthy that experiments requiring short-term MSP knockdown (as in Figures 4 and 6) were more successful using shRNA plasmid #2, whereas experiments requiring longer term knockdown of MSP (as in Figure 5 ) were performed more successfully with shRNA plasmid #1, apparently reflecting deleterious effects of extended strong suppression of MSP (data not shown). In addition, we generated a similar expression plasmid targeting the MSP receptor, RON; efficacy of this plasmid in downregulating RON mRNA levels was confirmed by realtime RT-PCR analysis ( Figure 3b ).
Next, H1299 cells were transiently transfected with plasmids expressing either control shRNA, or MSP shRNA (shMSP, plasmid #2) or with a plasmid encoding mutant p53 R175H, either alone or in combination with each other. At 48 h post-transfection, cells were treated with 10 mM etoposide for 48 h, and then harvested and fixed for cell cycle analysis by FACS. As seen in Figure 4 , the population of cells transfected with mutant p53 exhibited a significant reduction in the number of apoptotic (SubG1) cells compared to the control (compare panels a and b). This is consistent with earlier findings using similar conditions (Blandino et al., 1999) . The data probably underestimate the full protective effect of the transfected plasmids, since the entire culture was taken for analysis without prior gating, whereas only about 80% of the cells were successfully transfected, as assessed with the aid of a cotransfected GFP expression plasmid. Importantly, knockdown of MSP alone also had a marked protective effect under these conditions (panel c). It is noteworthy that combining mutant p53 overexpression with MSP knockdown did not lead to a further reduction in cell death (panel c); although this may be biologically significant, we cannot rule out the possibility that it is merely reflecting a technical limitation of the assay, for example, differences in cotransfection efficiencies or coexistence of multiple cell death mechanisms in a heterogeneous cell culture. Taken together, these results indicate that suppression of MSP expression can augment the resistance of H1299 lung cancer cells to genotoxic stress, similarly to what is observed with mutant p53 overexpression.
MSP is a secreted protein. Hence, it is conceivable that the effects of its downregulation are not cell autonomous, but rather may impinge also on neighboring cells. To investigate this notion, H1299 cells were Extracts from H1299 cells stably transfected with either a vector control (p53 null) or mutant p53 R175H (mp53), as well as H1299 cells transiently transfected with an expression plasmid encoding wt p53 (wtp53), were subjected to ChIP using anti-p53 polyclonal antibodies, as described in Materials and methods. The presence of MSP genomic sequences was subsequently detected by performing PCR reactions on the immunoprecipitated genomic DNA. The no antibody (no AB) reaction was performed with material from control immunoprecipitations performed with the chromatin of mutant p53-transfected cells, from which the 0.1% input sample was also derived. Figure 3 Functional validation of shRNA expression plasmids specific for MSP and RON. (a) H1299 cells plated in 6 cm dishes and subsequently transfected with 0.5 mg of a plasmid encoding a selectable drug resistance marker (pBabePuro) together with 4.5 mg of either a control (altered pSuper p53 control) shRNA expression plasmid (cont), two different MSP-specific shRNA expression plasmids (siMSP#1 and #2, respectively) or a plasmid expressing p53R175H (Mut p53). Following 48 h of puromycin selection, cells were incubated in serum-free medium for an additional 48 h. Medium was collected and concentrated using UltraFree MC 10kd centrifuge columns (Millipore). Concentrated medium was analysed by Western blot for MSP using monoclonal antibodies (R&D systems). The main specific band detected with these antibodies was the 53 kDa large cleavage product. GAPDH from the plated cells, harvested in parallel, was used as a loading control. (b) H1299 cells were transfected with a plasmid encoding puromycin resistance, along with a RON-specific shRNA expression plasmid (see Materials and methods). Drug selection was as in panel a. Cells were then harvested and total RNA was extracted. cDNA was synthesized and RON mRNA levels were analysed as described in Materials and methods.
Repression of MSP by mutant p53
A Zalcenstein et al transfected with either control shRNA or MSP shRNA #1 expression plasmids. Fresh culture medium was added 24 h after transfection and left on the cultures to be conditioned for an additional 48 h. The conditioned medium was subsequently removed and swapped between the two cell populations, at which time 10 mM etoposide was added for another 48 h before harvesting for DNA content analysis by FACS. As seen in Figure 5 , control-transfected cells incubated with conditioned medium from MSP shRNA-transfected cultures exhibited a mild but statistically significant decrease in apoptosis compared to control cells incubated with medium conditioned by control-transfected cells (compare second and first columns). This implies that the medium conditioned by MSP shRNA transfectants provides a more antiapoptotic microenvironment. Most probably, this is due to the decrease in secreted MSP protein, suggesting that the levels of MSP normally produced by H1299 cells facilitate the killing of these cells by genotoxic agents. Presumably, the decrease in apoptosis was rather moderate since, although the conditioned medium was partially depleted of MSP, the control cells were able to replenish it with this protein during the etoposide treatment. Conversely, the protective effect of MSP shRNA was markedly compromised when these cells were incubated with control medium, as compared to their own medium (columns 3 and 4, respectively). This was presumably due to the higher levels of MSP provided by the control medium. This 'functional rescue' experiment indicates that the effects of the shRNA were indeed most probably due to depletion of MSP from the microenvironment of the cells, rather than to some irrelevant off-target effects. Overall, these findings support the notion that reduced levels of secreted MSP can confer a survival advantage upon at least some types of cancer cells.
Knockdown of the MSP receptor, RON, also increases resistance of H1299 cells to DNA damage-induced apoptosis MSP is the only known ligand of the RON receptor. Thus, it was conceivable that downregulation of RON expression to below normal levels might recapitulate the prosurvival effect of MSP knockdown, at least to some extent. To explore this notion, H1299 cells were MSP expression is attenuated in a variety of human cancers As discussed above, numerous studies have implicated the MSP/RON pathway in cell survival and tumor progression. Based on this knowledge, one might have expected gain of function p53 mutants to exert a positive effect on this pathway, if any. Yet, our data argue the opposite and suggest that, at least in some cancer cell types, reduced MSP expression might offer a selective advantage, rather than a disadvantage. Indeed, analysis of publicly available gene expression microarray data comparing tumors versus their corresponding normal tissues, as rendered in www.oncomine.org (Rhodes et al., 2004) , reveals that MSP is significantly downregulated in numerous human cancers. In total, 11 data sets listed in this database yielded differences in MSP expression levels between tumor and normal tissue with P-values below 0.05; in six of these, MSP expression was lower in the cancer samples, whereas the opposite was seen in the other five ( Figure 7 ). Of particular note, a significant reduction in MSP expression was found also in large-cell lung carcinoma, the tumor type from which the H1299 cell line was derived (Figure 7 , analysis 11), suggesting that normal MSP levels confer a selective disadvantage upon this type of tumor cells. These data are elaborated in more detail in the Discussion.
Discussion
The work described in this report demonstrates that the MSP gene is transcriptionally downregulated by tumorassociated mutant p53, and that this downregulation contributes to increased resistance of large-cell lung carcinoma-derived cells to DNA damage-induced apoptosis. Hence, at least in this experimental system, constitutive basal activity of the MSP/RON pathway appears to facilitate apoptosis, and its attenuation by mutant p53 may thus afford enhanced survival and underscore a pro-oncogenic activity of such mutant p53 protein.
While our data show that MSP transcriptional repression can be elicited by two different 'hotspot' p53 mutants, R175H and R273H, it is presently unknown whether this is true for all tumor-associated p53 mutant p53 isoforms. Different mutants may indeed possess different biochemical and biological properties (Halevy et al., 1990; Hinds et al., 1990) , and may contribute to oncogenesis by different mechanisms. Moreover, combinations of different mutants within the same cell may have different effects than each of the mutants when expressed alone (Gurova et al., 2003; Demidenko et al., 2005) .
The mechanism whereby mutant p53 represses MSP gene expression is still largely unknown. However, our data indicate that mutant p53 is present on the MSP promoter; this raises the possibility that mutant p53 may either physically block the interaction of positive transcriptional regulators with the promoter or actively promote transcriptional repression, perhaps by recruitment of inhibitory proteins or by imposing restrictive chromatin modifications. Furthermore, it remains to be established whether mutant p53 associates directly with primary sequences or secondary structures in the DNA of the MSP promoter, as described recently for other mutant p53-binding targets (Gohler et al., 2005) , or is tethered to this promoter indirectly, via interaction with another DNA-binding protein.
Numerous earlier studies have implicated the MSP/ RON pathway in oncogenic transformation. RON activation was shown to be a major step in cell transformation by the JSRV retrovirus, an acutely oncogenic sheep virus (Miller et al., 2004) . Also, constitutively active forms of the RON receptor were shown to drive tumor cell motility by radically affecting cytoskeletal organization (Wang et al., 2004) , and excessive activity of the MSP/RON pathway was shown to increase cell survival in a variety of experimental settings (reviewed in Danilkovitch-Miagkova and Leonard, 2001 ). In vivo, RON was shown to promote lung tumor formation in transgenic mice expressing the receptor under the control of the protein C promoter (Chen et al., 2002b) , while xenografts of cells harboring point mutated, constitutively active RON led to the formation of highly aggressive, metastatic tumors (Peace et al., 2001) . Moreover, truncated, constitutively active forms of RON were shown to drive tumor progression (Bardella et al., 2004) . The picture that emerges from these studies is therefore highly consistent with a positive role of the MSP/RON pathway in cancer. Given this picture, our findings would seem counterintuitive, as they suggest that, at least in some cancer cell types, the MSP/RON pathway may actually reduce survival and potentially attenuate cancer progression.
However, further analysis of available information suggests that our findings may not be so unexpected.
Thus, while MSP stimulation can indeed protect some cultured cells from apoptosis, it actually promotes apoptosis in other, leukemia-derived cells (Iwama et al., 1996) . This argues that the effect of the MSP/ RON pathway on cell survival is highly cell context dependent, and may be substantially affected by tumorspecific alterations that occur during cancer progression.
Importantly, the analysis of gene expression patterns in a variety of human cancers reveals a significant downregulation of MSP RNA in a substantial number of tumor types (see Figure 7) . For instance, such downregulation was found to occur in hepatocellular carcinoma (Chen et al., 2002a) , where tumors expressing easily detectable levels of p53, usually indicative of p53 mutations, were observed to exhibit a consistent downregulation of MSP levels relative to p53-negative tumors. Similarly, a comparison of p53 mutationpositive and -negative breast carcinoma tumors (Sorlie et al., 2001 ) suggested a significant (P ¼ 0.001) correlation between downregulation of MSP expression and the presence of p53 gene mutations. Moreover, general comparison of benign breast tissue to breast carcinomas also indicated that, on average, breast carcinomas had significantly lower levels of MSP (P ¼ 0.017). An extensive study of the gene expression signature of prostate cancer (Dhanasekaran et al., 2001) , comparing cDNA array data for benign prostatic hyperplasia and normal prostate tissue to primary prostate cancer, also showed an extremely significant reduction of MSP levels in tumors (P ¼ 2.40EÀ06).
Another study (Higgins et al., 2003) characterized gene expression patterns in different types of kidney tumors. In all tumor types, at least some downregulation of MSP was observed relative to normal kidney tissue (granular renal cell carcinoma, P ¼ 0.013; clear renal cell carcinoma, P ¼ 0.081; chromophobe renal cell carcinoma P ¼ 0.235; papillary renal cell carcinoma, P ¼ 0.366). Similar results were also reported in a microarray study of pancreatic tumors (Iacobuzio-Donahue et al., 2003) , where pancreatic adenocarcinomas were found to express, on average, approximately 25% of the MSP levels of normal pancreatic tissues (as measured in normalized expression units; see www.oncomine.org; Rhodes et al., 2004) .
Most importantly for the present study, large-cell lung carcinoma tumors were found to have significantly (P ¼ 0.037) lower levels of MSP mRNA than normal lung tissue (Garber et al., 2001 ). As noted above, this is the tumor type from which H1299 cells, used in our experiments, were derived. This suggests that, in this type of cancer, normal MSP levels may be disadvantageous for tumor progression, and their downregulation by mutant p53 may therefore exert pro-oncogenic effects. It is of note that this varies greatly among different types of lung cancer; whereas squamous cell carcinomas of the lung also exhibit some reduction in MSP expression (P ¼ 0.083; Garber et al, 2001 ), the opposite is true for lung adenocarcinomas and carcinoids, where MSP is actually strongly upregulated (Bhattacharjee et al., 2001 ) see also Figure 7 , analyses 3 and 5, respectively).
With respect to RON expression in human tumors, the case is not clear-cut either. RON-mediated signaling has been implicated in many types of human epithelial malignancies (Camp et al., 2005) . It is noteworthy, however, that while the RON receptor is present on many types of epithelial cells, its contribution to cancer is observed only when it is either overexpressed or constitutively activated by mutations (Camp et al., 2005) . Hence, in cells retaining normal RON function, this may not necessarily be advantageous to cancer progression. In fact, our data suggest that, at least in some tumor cell types, the opposite may be true. Indeed, gene expression microarrays support this conjecture. For instance, a significant (P ¼ 7.7EÀ4) downregulation of RON expression was found in glioblastoma samples as compared to normal brain (Ramaswamy et al., 2001) . Similarly, reduced RON expression was found in squamous cell carcinomas (P ¼ 3.1EÀ4; Garber et al., 2001) , as well as in cutaneous follicular lymphoma and cutaneous diffuse large-B-cell lymphoma (Storz et al., 2003) . In summary, the impact of the MSP/RON pathway on cancer seems to be highly dependent on the type of cancer under analysis, probably involving different contributions of this pathway in different biological contexts.
Our data suggest that the MSP/RON pathway, while being pro-oncogenic in some circumstances, may actually be proapoptotic in others. This deleterious effect can be overcome by mutant p53 gain of function.
It is highly likely that whereas partial downregulation of MSP/RON pathway function may confer a selective advantage to some cancer cell types, complete abrogation of this pathway will have the opposite effect. This notion is supported by our observation that extended treatment with the more effective MSP siRNA plasmid (#2 in Figure 3a) eventually resulted in the death of H1299 cells (data not shown). In this regard, the moderate reduction effected by mutant p53 may provide just the right extent of impaired MSP/RON pathway function that is conducive to oncogenesis.
Finally, O'Farrell et al. (2004) have recently reported that MSP gene expression is downregulated by another p53 mutant, p53A138P, in HCT116 human colorectal cancer cells. Interestingly, in the same study, MSP was found to be downregulated also by wt p53, albeit to a lesser extent (about 1.8-fold). Our finding that wt p53 can associate with the MSP gene promoter, albeit perhaps less efficiently than mutant p53, is consistent with the notion that both types of p53 can target the MSP gene for transcriptional regulation. Tumorassociated p53 mutants such as p53R175H may therefore retain, and probably augment, a biochemical feature that is already present in the wt p53 protein. This feature is unlikely to rely on the ability of wt p53 to recognize target genes via its sequence-specific DNAbinding domain, an ability that is abrogated by the R175H mutation. It is conceivable that the downregulation of MSP expression by wt p53 may indeed serve to suppress cancer, for example, by attenuating RON-mediated survival signals or by reducing cell motility and metastasis. In contrast, in cells harboring p53 mutations, this downregulation occurs, and is even markedly augmented, in the absence of most other wt p53 activities (Blagosklonny, 2000; O'Farrell et al., 2004) . Under such circumstances, MSP downregulation may exert an opposite effect and actually contribute to the oncogenic gain of function capacities of such p53 mutants.
In conclusion, this study identifies transcriptional repression of the MSP gene as a new component in the antiapoptotic gain of function activity of tumorassociated mutant p53. Together with additional mutant p53-dependent transcriptional effects, such as downregulation of CD95/Fas expression (Zalcenstein et al., 2003) and upregulation of Egr1 gene expression (Weisz et al., 2004) , this may render cancer cells more resistant to chemotherapy. Interfering with the expression or function of mutant p53 may thus sensitize tumor cells to elimination by therapy.
Materials and methods
Cells, plasmids and transfections H1299 cells (ATCC) were maintained in RPMI medium (Sigma) supplemented with 10% fetal calf serum (FCS; Sigma).
Plasmid pCMV-neo-Bam-p53R175H was obtained from W Kaelin. siRNA plasmids encoding shRNA specific for MSP and RON, and control shRNA derived from pSuper-p53 by insertion of three base-paired mismatches in the p53-specific sequence (Brummelkamp et al., 2002) , were constructed according to Brummelkamp et al. (2002) . Briefly, 64 bp oligonuclotides (listed below) were synthesized by Sigma (Israel), and annealed in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM magnesium acetate). Oligonucleotides were then phosphorylated with T4 polynucleotide kinase, and ligated into pSuper pre-cut with BglII and HindIII and dephosphorylated with calf intestinal phosphatase. Escherichia coli DH5a bacteria were then transformed with the ligated constructs and positive clones were selected. MSP-luciferase reporter plasmid was constructed by cloning the MSP promoter into a pGL3-basic plasmid (Promega). The promoter region itself was obtained by amplification from genomic DNA using specific primers (sense CTA CTC CCG CCA CAA ACC and antisense CTT CTG GCT GGA GGC TGC AC).
shRNA oligonucleotides used The following oligonucleotides were used: altered p53Super control, forward: GAT CCCC GACTCCCGTTGTAATC TAC TTC AAG AGA GTAGATTACAACGGGAGTC TTTTT GG AAA; altered p53Super control, reverse: AGC  TTTT CC AAAAA GACTCCCGTTGTAATCTAC TCT  CTT GAA GTAGATTACAACGGGAGTC GGG; MSP#1,  forward: GAT CCCC GGAGCAGTGGATACTGACT TTC  AAG AGA AGTCAGTATCCACTGCTCC TTTTT GG A  AA; MSP#1 reverse: AGC TTTT CC AAAAA GGAGCAG  TGGATACTGACT TCT CTT GAA AGTCAGTATCCACT  GCTCC GGG; MSP#2, forward: GAT CCCCGAGGCCA  CAACTGTCAGCT TTC AAG AGAAGCTGACAGTTGT  GGCCTC TTTTT GG AAA; MSP#2, reverse: AGC TTTT  CC AAAAA GAGGCCACAACTGTCAGCT TCT CTT  GAA AGTCAGTATCCACTGCTCC GGG; RON, forward:  GAT CCCC GATGAATCCTGTGTGCCAC TTC AAG AGA GTGGCACACAGGATTCATC TTTTT GG AAA;  RON, reverse: AGC TTTT CC AAAAA GATGAATCCTG  TGTGCCAC TCT CTT GAA GTGGCACACAGGATT  CATC GGG. For all transfections, cells were transfected using Fugene (Roche) at a ratio of 2 mg DNA:3 ml Fugene, according to the manufacturer's instructions.
Western blot analysis
Secreted MSP levels were analysed by growing cells in serumfree medium for 48 h. Medium was then collected and concentrated using Millipore UltraFree MC 10 kd columns. Protein sample buffer was added to the medium concentrates, which were then resolved by SDS-PAGE on a 10% polyacrylamide gel and probed with monoclonal anti-MSP antibodies (AF352, R&D systems), followed by secondary goat anti-mouse HRP-conjugated antibodies (Jackson). Membranes were developed using the ECL kit (Amersham). To determine GAPDH levels in corresponding cell populations, cells were lysed in protein sample buffer and analysed as above using monoclonal anti-GAPDH antibodies (MAB374, Chemicon). p53 levels in cell lysates were determined as above, using a mix of monoclonal antibodies DO-1 and PAb1801. Tubulin levels were probed using a polyclonal anti-a-tubulin antibody (T-7816, Sigma), followed by secondary goat anti-rabbit HRPconjugated antibodies (Jackson).
Chromatin immunoprecipitation analysis
For ChIP analysis, extracts were prepared from H1299 cells stably transfected with either a mutant p53 expression plasmid or control vector; alternatively, extracts were prepared from H1299 cells transiently transfected for 48 h with an expression plasmid encoding wt p53 (Weisz et al., 2004) . ChIP was performed essentially as described (Weinmann and Farnham, 2002) , except that lysates from 3 Â 10 7 H1299 cells stably expressing p53R175H were diluted fivefold in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH 8.1, 167 mM NaCl), and bound complexes were collected with protein A-agarose beads crosslinked to anti-p53 rabbit polyclonal antibody by DMP, as described earlier (Weisz et al., 2004) . PCR of the MSP promoter was performed using the oligonucleotides 5 0 -CTCACTGATGTG TAGCGGTGCT-3 0 (forward) and 5 0 -TGTCCAACAGAG TAACCATTAGCC-3 0 (reverse).
Luciferase assays
Luciferase assays were performed using (D)-luciferin (Roche). Luminescence was determined with the aid of a Rosys-Anthos Lucy 3 luminometer.
Apoptosis assays
For analysis of apoptosis by PI exclusion, cells were washed twice with PBS, treated for 1 min with 0.05% trypsin-EDTA solution (Bet-Haemek, Israel), and rapidly washed again with PBS. Cells were dislodged from the dish by pipetting, and then centrifuged and resuspended in PBS containing 1 mg/ml PI (Sigma) for 30 min before being analysed with the aid of a FACSORT double laser flow cytometer. To measure apoptosis by DNA content analysis, attached and floating cells were combined, harvested and fixed in cold methanol for at least 25 min. Cells were then rehydrated in PBS for at least 30 min, and treated with 25 mg/ml PI and 50 mg/ml RNAse A for at least 10 min, and then analysed with the aid of a FACSORT double laser flow cytometer.
RNA quantification
For real-time RT-PCR analysis, total RNA was extracted using the Nucleo-Spin RNA II kit (Macherey Nagel). A 2 mg portion of each RNA samplewas reverse transcribed using MMLV reverse transcriptase (Promega). Real-time PCR to quantify MSP expression was conducted on an ABgene 7000 sequence detection system using default amplification protocols (sense: ACA AGC CGC AGT TCA CGT TT, antisense: TCT CCT CCA GTT GTG CAT GC). cDNA levels were normalized to GAPDH (sense: ACC CAC TCC TCC ACC TTT GA, antisense: CTG TTG CTG TAG CCA AAT TCG T). RON expression was quantified similarly, using the following primers; sense: GCG ATT GCG TAT GGC TAC AAA, antisense: TAC GAG GGC GAC AGA AAT GAG.
For semiquantitative RT-PCR, RNA was extracted and reverse transcribed as above. cDNA levels were normalized by comparing relative GAPDH levels, amplified with the appropriate primers (sense: ACCACAGTCGCCATCAC, antisense: TCCACCACCCTGTTGCTGTA). An approximately 400 bp fragment of the MSP mRNA was amplified using specific primers (sense: CCA GAG CTG CGG CAT CAA ATC C, antisense: GTT CGG AGG TAA ACG TGA ACT GC).
